Reports / Nephrology Reports / RealTime Dynamix: Renal Anemia US
RealTime Dynamix: Renal Anemia US (quarterly)
This quarterly report series focuses on tracking key performance metrics for ESAs and iron products (oral iron, IV iron and dialysate iron) in both the dialysis and CKD-ND settings. Emphasis is placed on the growing familiarity with pipeline agents as well as the evolving role of Keryx’s Auryxia as a treatment for iron-deficiency anemia in non-dialysis patients. The rapid field-to-insight turnaround, highly relevant content, and unparalleled market understanding make RealTime Dynamix™ an essential tool for companies with commercial products in the space, those that will soon be launching and those looking for business development opportunities in nephrology.
This quarterly report has been fielded since Q1 2016.
Learn more about RealTime Dynamix™ reports here.
- What shifts are occurring in renal anemia in the dialysis setting and do these changes vary by chain (i.e. DaVita, FMC)?
- How do treatment rates and approaches for ESAs and IV iron differ between dialysis and CKD-ND patients?
- Do nephrologists have a preference for long-acting or short-acting ESAs and what does this mean for biosimilar ESAs coming to market? Will it impact HIF-PH inhibitor adoption?
- What is the market uptake for Rockwell Medical’s Triferic?
- Are nephrologists using Auryxia for the dual action of phosphate lowering and improvement in anemia parameters? How has the IDA launch of Auryxia expanded use and perceptions of the product?
- How does in-office infusion for IV iron or stocking of ESAs influence treatment rates and brand preference?
- How does the unmet need for new anemia drugs compare to the unmet need in other areas of nephrology?
- How are nephrologists becoming familiar with the HIF-Ph inhibitors, where will these agents likely play and how will they be differentiated from ESAs and, more importantly, from each other?
AMAG (Feraheme), Amgen (Aranesp, Epogen), American Regent/Luittpold/Vifor (Injectafer), FMC, generics (Venofer ), FMC/Roche (Mircera), Janssen (Procrit), Keryx (Auryxia), Rockwell Medical (Triferic), Sanofi-Genzyme, generics (Ferrlecit)
Akebia/Mitsubishi/Otsuka (Vadadustat), AstraZeneca/Astellas/Fibrogen (Roxadustat), Bayer (Molidustat), GSK (Daprodustat), Hospira/VFMCRP (Retacrit)
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia’s Auryxia, Amgen’s Parsabiv, and Opko’s Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products – June 25, 2019
Pfizer’s Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market – July 31, 2018
The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia Indication in the Pre-Dialysis Setting – May 8, 2018